Newsroom

Publications

New Scientific Publication

We are pleased to announce our newest paper in Cancers MDPI is now published online! This work unveils the potential of Apmonia Therapeutics’ lead candidate TAX2 (AP-01)

READ MORE »
Publications

New Scientific Publication

Apmonia Therapeutics’ lead program (AP-01 or TAX2) is a cyclic peptide targeting TSP-1 (a ligand of CD47 receptor) across various tumor indications with high unmet

READ MORE »
Overall News

Business Angels Marne-Ardennes

We are extremely pleased and enthusiastic that we can count upon the valued support of Business Angels Marne-Ardennes (BAMA, former Reims Business Angels)!  This enables Apmonia Therapeutics to

READ MORE »
Press Release

Apmonia Tx Press release

Check out Apmonia Therapeutics’ press release on the company’s corporate organization and i-Lab innovation award.#deeptech #biotech #cancer #reims

READ MORE »